Clinical trial · Interventional
Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors (Study P01964)(COMPLETED)
Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors
NCT00040547CI-TRIAL-00016891completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the safety and tolerability of an oral Farnesyl Protein Transferase Inhibitor (SCH 66336) when given in combination with intravenous docetaxel in cancer patients with advanced solid tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Farnesyl Protein Transferase Inhibitor | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Adverse Events
- measure
- Laboratory Tests
- measure
- ECG
Secondary outcomes (3)
- measure
- Physical Exam
- measure
- Pharmacokinetics
- measure
- Tumor Response
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion: * Male or Female * Measurable or evaluable disease * No more than 2 prior chemotherapy regimens. * Age greater than or equal to 18. * Karnofsky Performance Status greater than or equal to 70%. * Meets protocol requirements for specified laboratory values. * No manifestations of a malabsorption syndrome. * Written informed consent and cooperation of patient * Appropriate use of effective contraception if of child-bearing potential. Exclusion: * Acute or chronic leukemia or multiple myeloma. * Evidence of 2 or more active malignancies, expect for in situ or adequately treated basal or squamous cell skin cancer.
References
Publications (0)
Data not yet available
No reference posted for this study.